Simon T. Barry

13.8k total citations · 3 hit papers
123 papers, 6.1k citations indexed

About

Simon T. Barry is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Simon T. Barry has authored 123 papers receiving a total of 6.1k indexed citations (citations by other indexed papers that have themselves been cited), including 67 papers in Molecular Biology, 43 papers in Oncology and 26 papers in Cancer Research. Recurrent topics in Simon T. Barry's work include PI3K/AKT/mTOR signaling in cancer (19 papers), Cell Adhesion Molecules Research (14 papers) and Angiogenesis and VEGF in Cancer (12 papers). Simon T. Barry is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (19 papers), Cell Adhesion Molecules Research (14 papers) and Angiogenesis and VEGF in Cancer (12 papers). Simon T. Barry collaborates with scholars based in United Kingdom, United States and Germany. Simon T. Barry's co-authors include David R. Critchley, Jennifer I. Hare, Marianne Ashford, Sanyogitta Puri, Twan Lammers, Gert Storm, David C. Blakey, Uma Prabhakar, Omid C. Farokhzad and William C. Zamboni and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Simon T. Barry

118 papers receiving 6.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Challenges and Key Considerations of the Enhanced Permeability and Retention Effect for Nanomedicine Drug Delivery in Oncology

2013 1.2k citations Simon T. Barry, David C. Blakey et al. Cancer Research profile →
Challenges and strategies in anti-cancer nanomedicine development: An industry perspective

2016 900 citations Marianne Ashford, Simon T. Barry et al. profile →
Therapeutic targeting of tumour myeloid cells

2023 168 citations Simon T. Barry, Owen J. Sansom et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Simon T. Barry United Kingdom	38	2.8k	1.5k	1.4k	1.4k	936	123	6.1k
Kazuki N. Sugahara United States	35	4.0k 1.4×	1.7k 1.1×	1.9k 1.4×	1.1k 0.8×	1.2k 1.2×	56	6.6k
Tambet Teesalu Estonia	46	4.3k 1.5×	2.1k 1.4×	2.1k 1.5×	1.2k 0.9×	296 0.3×	119	7.4k
Wayne L. Monsky United States	27	1.7k 0.6×	1.6k 1.1×	1.4k 1.0×	895 0.7×	289 0.3×	84	5.2k
W. Gregory Roberts United States	24	2.5k 0.9×	1.7k 1.1×	1.2k 0.9×	784 0.6×	686 0.7×	30	5.5k
Pirjo Laakkonen Finland	37	3.2k 1.2×	934 0.6×	805 0.6×	1.4k 1.1×	324 0.3×	86	5.8k
Marcel Garcia France	45	2.7k 1.0×	1.1k 0.7×	660 0.5×	1.2k 0.9×	474 0.5×	146	6.2k
Kandice R. Levental United States	30	3.3k 1.2×	1.6k 1.1×	639 0.5×	1.5k 1.1×	2.6k 2.8×	60	6.7k
Steve R. Roffler Taiwan	42	3.4k 1.2×	905 0.6×	1.1k 0.8×	1.3k 1.0×	279 0.3×	168	6.1k
Bryan Ronain Smith United States	33	2.4k 0.9×	2.2k 1.4×	1.2k 0.9×	1.6k 1.1×	238 0.3×	90	7.4k
Venkata Ramana Kotamraju United States	36	3.7k 1.3×	2.2k 1.5×	2.3k 1.7×	1.1k 0.8×	173 0.2×	51	6.4k

Countries citing papers authored by Simon T. Barry

Since Specialization

Citations

This map shows the geographic impact of Simon T. Barry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Simon T. Barry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Simon T. Barry more than expected).

Fields of papers citing papers by Simon T. Barry

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Simon T. Barry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Simon T. Barry. The network helps show where Simon T. Barry may publish in the future.

Co-authorship network of co-authors of Simon T. Barry

This figure shows the co-authorship network connecting the top 25 collaborators of Simon T. Barry. A scholar is included among the top collaborators of Simon T. Barry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Simon T. Barry. Simon T. Barry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Willis, Brandon S., Hannah Dry, Wendan Xu, et al.. (2024). Potent combination benefit of the AKT inhibitor capivasertib and the BCL-2 inhibitor venetoclax in diffuse large B cell lymphoma. Leukemia. 38(12). 2663–2674. 2 indexed citations

Maxwell, Pamela, et al.. (2024). Targeting IL-8 and Its Receptors in Prostate Cancer: Inflammation, Stress Response, and Treatment Resistance. Cancers. 16(16). 2797–2797. 6 indexed citations

Fernández‐Teruel, Carlos, Marie Cullberg, Cath Eberlein, Simon T. Barry, & Diansong Zhou. (2024). Population Pharmacokinetics of Capivasertib in Patients with Advanced or Metastatic Solid Tumours. Clinical Pharmacokinetics. 63(8). 1191–1204. 3 indexed citations

Martin, Timothy D., Haley E. Manchester, Nicole S. Persky, et al.. (2024). Targeting Cholesterol Biosynthesis with Statins Synergizes with AKT Inhibitors in Triple-Negative Breast Cancer. Cancer Research. 84(19). 3250–3266. 12 indexed citations

Xu, Wendan, Philipp Berning, Tabea Erdmann, et al.. (2022). mTOR inhibition amplifies the anti-lymphoma effect of PI3Kβ/δ blockage in diffuse large B-cell lymphoma. Leukemia. 37(1). 178–189. 18 indexed citations

Berlato, Chiara, Eleni Maniati, Anissa Lakhani, et al.. (2021). Chemotherapy Induces Tumor-Associated Macrophages that Aid Adaptive Immune Responses in Ovarian Cancer. Cancer Immunology Research. 9(6). 665–681. 38 indexed citations

Strittmatter, Nicole, R. England, Alan Race, et al.. (2021). Method to Investigate the Distribution of Water-Soluble Drug-Delivery Systems in Fresh Frozen Tissues Using Imaging Mass Cytometry. Analytical Chemistry. 93(8). 3742–3749. 6 indexed citations

Carnevalli, Larissa S., Molly A. Taylor, Matthew King, et al.. (2021). Macrophage Activation Status Rather than Repolarization Is Associated with Enhanced Checkpoint Activity in Combination with PI3Kγ Inhibition. Molecular Cancer Therapeutics. 20(6). 1080–1091. 14 indexed citations

Barry, Simon T., et al.. (2021). Depression and Anxiety in Residents of a Retirement Community during the Covid-19 Pandemic. 8(9). 1 indexed citations

10.

Peel, S, et al.. (2021). Mutational inactivation of Apc in the intestinal epithelia compromises cellular organisation. Journal of Cell Science. 134(2). 2 indexed citations

11.

Marqués, Miriam, Robin Tranchant, Luis C. Fernández, et al.. (2020). Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features. Cancer Research. 80(4). 843–856. 21 indexed citations

12.

Floc’h, Nicolas, Susan Ashton, Douglas Ferguson, et al.. (2019). Modeling Dose and Schedule Effects of AZD2811 Nanoparticles Targeting Aurora B Kinase for Treatment of Diffuse Large B-cell Lymphoma. Molecular Cancer Therapeutics. 18(5). 909–919. 16 indexed citations

13.

Lynch, James T., Urszula M. Polanska, Oona Delpuech, et al.. (2018). Combined Inhibition of PI3Kβ and mTOR Inhibits Growth of PTEN-null Tumors. Molecular Cancer Therapeutics. 17(11). 2309–2319. 18 indexed citations

14.

Floc’h, Nicolas, Susan Ashton, Paula Taylor, et al.. (2017). Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles. Molecular Cancer Therapeutics. 16(6). 1031–1040. 29 indexed citations

15.

Lynch, James T., Urszula M. Polanska, Oona Delpuech, et al.. (2017). Inhibiting PI3Kβ with AZD8186 Regulates Key Metabolic Pathways in PTEN-Null Tumors. Clinical Cancer Research. 23(24). 7584–7595. 24 indexed citations

16.

Driscoll, David R., Saadia A. Karim, Makoto Sano, et al.. (2016). mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer. Cancer Research. 76(23). 6911–6923. 58 indexed citations

17.

Estrada, Marta F, Sofia P. Rebelo, Emma Jane Davies, et al.. (2015). Modelling the tumour microenvironment in long-term microencapsulated 3D co-cultures recapitulates phenotypic features of disease progression. Biomaterials. 78. 50–61. 93 indexed citations

18.

Smith, Neil R., Dawn Baker, Matthew R. Farren, et al.. (2013). Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy. Clinical Cancer Research. 19(24). 6943–6956. 111 indexed citations

19.

Jenkins, David W., Sarah J. Ross, Margaret H. Veldman-Jones, et al.. (2012). MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis In Vivo. Molecular Cancer Therapeutics. 11(8). 1650–1660. 47 indexed citations

20.

Brave, Sandra R., Kirsty Ratcliffe, Zena Wilson, et al.. (2011). Assessing the Activity of Cediranib, a VEGFR-2/3 Tyrosine Kinase Inhibitor, against VEGFR-1 and Members of the Structurally Related PDGFR Family. Molecular Cancer Therapeutics. 10(5). 861–873. 72 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact